Efthymios Deliargyris
Chief Tech/Sci/R&D Officer en CYTOSORBENTS CORPORATION .
Fortuna: 388 961 $ al 31/03/2024
Perfil
Efthymios N.
Deliargyris is currently the Chief Medical Officer at CytoSorbents Corp.
He previously held the same position at PLx Pharma, Inc. from 2018 to 2020.
Prior to that, he was the Director of Cardiology and Interventional Cardiology at Athens Medical Center SA from 2004 to 2010, and an Assistant Professor at Wake Forest University from 2001 to 2004.
Deliargyris earned a doctorate degree from the National & Kapodistrian University of Athens.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CYTOSORBENTS CORPORATION
0.78% | 02/04/2024 | 409 433 ( 0.78% ) | 388 961 $ | 31/03/2024 |
Cargos activos de Efthymios Deliargyris
| Empresas | Cargo | Inicio |
|---|---|---|
| CYTOSORBENTS CORPORATION | Chief Tech/Sci/R&D Officer | 01/05/2020 |
Antiguos cargos conocidos de Efthymios Deliargyris.
| Empresas | Cargo | Fin |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Chief Tech/Sci/R&D Officer | 30/04/2020 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 01/01/2010 |
| Wake Forest University | Corporate Officer/Principal | 01/01/2004 |
Formación de Efthymios Deliargyris.
| National & Kapodistrian University of Athens | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| CYTOSORBENTS CORPORATION | Health Technology |
| Empresas privadas | 1 |
|---|---|
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
- Bolsa de valores
- Insiders
- Efthymios Deliargyris
